

Daratumumab plus CyBorD for patients with newly dia results of ANDROMEDA

Blood

136, 71-80

DOI: [10.1182/blood.2019004460](https://doi.org/10.1182/blood.2019004460)

Citation Report

#	ARTICLE	IF	CITATIONS
1	AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 3778.	1.0	6
2	Management of AL amyloidosis in 2020. <i>Blood</i> , 2020, 136, 2620-2627.	0.6	133
3	Management of AL amyloidosis in 2020. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 363-371.	0.9	34
4	Worldwide Perspectives of Amyloidosis. <i>Acta Haematologica</i> , 2020, 143, 301-303.	0.7	2
5	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. <i>Frontiers in Pharmacology</i> , 2020, 11, 1024.	1.6	25
6	Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. <i>Expert Review of Hematology</i> , 2020, 13, 1003-1015.	1.0	5
7	Emerging drugs for the treatment of light chain amyloidosis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 299-317.	1.0	10
8	Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 11, a034900.	2.9	0
9	Systemic Amyloidosis due to Monoclonal Immunoglobulins. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1055-1068.	0.9	5
10	Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1145-1159.	0.9	8
11	Systemic Amyloidosis due to Low-Grade Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1027-1039.	0.9	8
12	Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1081-1090.	0.9	4
13	Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. <i>Blood Advances</i> , 2020, 4, 4175-4179.	2.5	24
14	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. <i>HemaSphere</i> , 2020, 4, e454.	1.2	28
15	Light-chain amyloid myopathy isolated to skeletal muscles: A case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2869-2873.	0.2	1
16	Future Perspectives. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 1205-1214.	0.9	4
17	Acquired and inherited amyloidosis: Knowledge driving patients' care. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 85-101.	1.4	12
18	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Diagnosis and management of systemic light chain AL amyloidosis. , 2020, 214, 107612.		3
20	Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. <i>Journal of Nephrology</i> , 2021, 34, 231-240.	0.9	2
21	Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment. <i>Leukemia and Lymphoma</i> , 2021, 62, 979-983.	0.6	5
22	Daratumumab for relapsed AL amyloidosisâ€”When cumulative realâ€world data precedes clinical trials: A multisite study and systematic literature review. <i>European Journal of Haematology</i> , 2021, 106, 184-195.	1.1	14
23	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. <i>Oncolmmunology</i> , 2021, 10, 1859263.	2.1	13
24	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072098707.	1.1	10
25	Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 80-88.	0.3	0
27	Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. <i>Frontiers in Oncology</i> , 2020, 10, 624573.	1.3	5
28	Cardiac amyloidosisâ€”A review of current literature for the practicing physician. <i>Clinical Cardiology</i> , 2021, 44, 322-331.	0.7	32
29	Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. <i>Cells</i> , 2021, 10, 545.	1.8	24
30	Updates in Cardiac Amyloidosis Diagnosis and Treatment. <i>Current Oncology Reports</i> , 2021, 23, 47.	1.8	17
31	Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management. <i>Diagnostics</i> , 2021, 11, 420.	1.3	4
32	The long and winding road to target protein misfolding in cardiovascular diseases. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13504.	1.7	16
33	Cardiac Amyloidosis. , 0, , .		0
34	Venetoclax induces profound and sustained responses in patients with relapsed/refractory lightâ€chain amyloidosis. <i>British Journal of Haematology</i> , 2021, 193, 674-677.	1.2	9
35	First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience. <i>ESMO Open</i> , 2021, 6, 100065.	2.0	8
36	Autologous stem cell transplantation in the age of ANDROMEDA. <i>British Journal of Haematology</i> , 2021, 193, 865-866.	1.2	3
37	Diagnosis and Treatment of AL and ATTR Amyloidosis. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 329-332.	0.2	0

#	ARTICLE	IF	CITATIONS
38	Scalloped Tongue in Primary Amyloidosis. <i>Journal of General Internal Medicine</i> , 2021, 36, 2456-2457.	1.3	1
39	Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy. <i>Cureus</i> , 2021, 13, e15102.	0.2	2
40	Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. <i>Blood Cancer Journal</i> , 2021, 11, 90.	2.8	27
41	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021, 35, 3604-3607.	3.3	8
42	From VAD to VRD. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 190-195.	1.0	1
43	Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. <i>Blood Cancer Journal</i> , 2021, 11, 118.	2.8	15
44	Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 357-366.	1.2	6
45	Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. <i>ESC Heart Failure</i> , 2021, 8, 2380-2396.	1.4	29
46	A randomized phase 3 study of ixazomib+dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2022, 36, 225-235.	3.3	29
48	Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 182-188.	1.4	4
49	Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e970-e974.	0.2	1
50	Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 470-475.	0.2	11
51	Hepatic AL Amyloidosis Without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab. <i>American Journal of Case Reports</i> , 2021, 22, e933241.	0.3	0
52	Cardiac Amyloidosis: from Heart Failure to Multiple Myeloma, a Case Report. <i>Revista Romana De Cardiologie</i> , 2021, 31, 373-378.	0.0	0
53	Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options. <i>Revista Romana De Cardiologie</i> , 2021, 31, 283-302.	0.0	1
54	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
55	Two Decades of Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2021, 3, 522-533.	1.7	20
56	Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30.	1.4	0


#	ARTICLE	IF	CITATIONS
57	Posicionamento sobre Diagnóstico e Tratamento da Amiloidose Cardíaca 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 561-598.	0.3	35
58	Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial. Circulation, 2022, 145, 8-17.	1.6	25
59	How I treat AL amyloidosis. Blood, 2022, 139, 2918-2930.	0.6	31
60	The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110400.	0.2	1
61	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007931.	1.6	15
62	Current Updates on the Management of AL Amyloidosis. Journal of Hematology (Brossard, Quebec), 2021, 10, 147-161.	0.4	9
63	Case Report: Management of Primary Tracheobronchial Light Chain Amyloidosis in a Patient With Biclonal Gammopathy Using a Systemic Bortezomib-Based Regimen. Frontiers in Medicine, 2021, 8, 728561.	1.2	1
64	Evaluation of subcutaneous daratumumab injections in the ambulatory care setting. Journal of Oncology Pharmacy Practice, 2021, , 107815522110469.	0.5	3
65	Recurrent Glomerular Disease after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1730-1742.	2.2	29
66	Advances in diagnostics and therapy of systemic amyloidoses. Reumatologia, 2020, 58, 343-344.	0.5	1
67	Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	0
68	Diagnosis of amyloid beyond Congo red. Current Opinion in Nephrology and Hypertension, 2021, 30, 303-309.	1.0	9
69	Predictive factors of outcomes in patients with <scp>AL</scp> amyloidosis treated with daratumumab. American Journal of Hematology, 2022, 97, 79-89.	2.0	10
70	Clinical and morphological spectrum and long-term outcome in monoclonal gammopathy of renal significance: one center study. Nephrology (Saint-Petersburg), 2020, 24, 19-27.	0.1	1
72	Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	1.1	5
73	COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e321-e326.	0.2	9
74	T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy. Clinical and Translational Medicine, 2021, 11, e582.	1.7	0
75	Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics, 2021, 18, 2286-2302.	2.1	8

#	ARTICLE	IF	CITATIONS
76	De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. <i>HemaSphere</i> , 2021, 5, e665.	1.2	0
77	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
78	Daratumumab: A review of current indications and future directions. <i>Seminars in Oncology</i> , 2022, 49, 48-59.	0.8	4
79	Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. <i>American Journal of Medicine</i> , 2022, 135, S30-S37.	0.6	2
80	Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	0.6	1
81	Amyloid Cardiomyopathy in Older Adults. <i>Current Geriatrics Reports</i> , 2022, 11, 1.	1.1	0
82	Amyloidosis from the patient perspective: the French daily impact of amyloidosis study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 165-174.	1.4	17
83	Daratumumab for Immunoglobulin Light Chain Amyloidosis. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 79.	0.1	0
84	A Short Review of Hematopoietic Transplantation for AL Amyloidosis. , 0, , .		0
85	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. <i>Internal and Emergency Medicine</i> , 2022, 17, 957-969.	1.0	6
86	Systematic literature review of evidence in amyloid light-chain amyloidosis. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 451-472.	0.6	1
87	Nomogram Model for Dynamic and Individual Prediction of Cardiac Response and Survival for Light Chain Amyloidosis in 737 Patients With Cardiac Involvement. <i>Frontiers in Oncology</i> , 2021, 11, 758502.	1.3	1
88	An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05176.	0.2	0
89	Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis. <i>Drugs</i> , 2022, 82, 683-690.	4.9	2
90	Cutaneous manifestations of monoclonal gammopathy. <i>Blood Cancer Journal</i> , 2022, 12, 58.	2.8	11
91	Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. <i>American Journal of Hematology</i> , 2022, 97, 818-829.	2.0	39
94	Cardiac Amyloidosis: A Rare Cause of Recurrent Chylothorax. <i>Cureus</i> , 2022, , .	0.2	0
95	Multidisciplinary supportive care in systemic light chain amyloidosis. <i>Blood Research</i> , 2022, 57, 106-116.	0.5	5

#	ARTICLE	IF	CITATIONS
96	Immunotherapy in AL Amyloidosis. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1059-1071.	1.3	3
97	Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25-€year longitudinal study. <i>American Journal of Hematology</i> , 2022, 97, 1189-1199.	2.0	12
98	Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
99	Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2383-2392.	0.6	8
100	Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 479-488.	1.0	4
101	Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment. <i>BMJ Case Reports</i> , 2022, 15, e249737.	0.2	2
102	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	1.4	22
103	Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis. <i>Blood Advances</i> , 2022, 6, 5436-5439.	2.5	1
104	Global epidemiology of amyloid light-chain amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, .	1.2	18
105	Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma. <i>Blood Science</i> , 0, Publish Ahead of Print, .	0.4	1
106	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e333-e465.	0.5	97
107	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal</i> , 2022, 43, 4229-4361.	1.0	705
108	A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone. <i>Case Reports in Hematology</i> , 2022, 2022, 1-7.	0.3	2
109	Targeting CD38 in Neoplasms and Non-Cancer Diseases. <i>Cancers</i> , 2022, 14, 4169.	1.7	10
110	Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective. <i>Expert Review of Hematology</i> , 2022, 15, 781-788.	1.0	6
111	Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina. <i>PLoS ONE</i> , 2022, 17, e0274578.	1.1	3
112	Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. <i>Onkologie (Czech Republic)</i> , 2022, 16, 61-82.	0.0	0
113	Multidisciplinary amyloidosis care in the era of personalized medicine. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

114			
-----	--	--	--



#	ARTICLE	IF	CITATIONS
134	Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis. European Heart Journal Supplements, 2023, 25, B79-B84.	0.0	5
141	Hematologic Malignancies. , 2023, , 5-21.		0